Cibinetide

Cibinetide
Clinical data
Other names	ARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS
Drug class	Erythropoietin receptor agonist
Identifiers
	IUPAC name (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid;
CAS Number	1208243-50-8;
PubChem CID	91810664;
DrugBank	DB13006;
ChemSpider	35013013;
UNII	9W5677JKDA;
KEGG	D11218;
ChEMBL	ChEMBL3545305;
Chemical and physical data
Formula	C51H84N16O21
Molar mass	1257.324 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1;
	InChI InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1; Key:WZTIQQBMSJTRBR-WYKNNRPVSA-N;

Cibinetide (INNTooltip International Nonproprietary Name; USANTooltip United States Adopted Name; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions.^[1]^[2]^[3] It was also under development for the treatment of depressive disorders, but development for this indication was discontinued.^[1] The drug is under development by Araim Pharmaceuticals.^[1]^[2]

References

^ ^a ^b ^c ^d "Cibinetide - Araim Pharmaceuticals". AdisInsight. 28 June 2022. Retrieved 23 October 2024.
^ ^a ^b ^c "Delving into the Latest Updates on Cibinetide with Synapse". Synapse. 8 October 2024. Retrieved 23 October 2024.
^ Peng B, Kong G, Yang C, Ming Y (February 2020). "Erythropoietin and its derivatives: from tissue protection to immune regulation". Cell Death Dis. 11 (2): 79. doi:10.1038/s41419-020-2276-8. PMC 6997384. PMID 32015330.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "Cibinetide - Araim Pharmaceuticals". AdisInsight. 28 June 2022. Retrieved 23 October 2024.

[Synapse-2] "Delving into the Latest Updates on Cibinetide with Synapse". Synapse. 8 October 2024. Retrieved 23 October 2024.

[PengKongYang2020-3] Peng B, Kong G, Yang C, Ming Y (February 2020). "Erythropoietin and its derivatives: from tissue protection to immune regulation". Cell Death Dis. 11 (2): 79. doi:10.1038/s41419-020-2276-8. PMC 6997384. PMID 32015330.

[1]

[2]

[3]